Skip to main content
SpringerLink
Log in

Selektive Serotonin-Wiederaufnahmehemmer bei therapieresistenten und schweren Depressionen

  • Chapter
Akute und therapieresistente Depressionen

  • 4497 Accesses

Zusammenfassung

Die selektiven Serotonin-Wiederaufnahmehemmer (SSRI) gehören zu den am häufigsten verschriebenen psychiatrischen Medikamenten. Für leichte und mittelschwere depressive Syndrome liegen metaanalytische Daten vor, die eine vergleichbare Wirksamkeit mit trizyklischen Antidepressiva (TZA) zeigen. Bislang mangelt es jedoch an unabhängigen Studien zur Wirksamkeit der SSRI bei schweren und therapieresistenten Depressionen im Vergleich zu anderen antidepressiven Wirkstoffgruppen. Die vorhanden Ergebnisse interpretieren wir im Sinne einer geringfügig besseren Wirksamkeit der TZA gegenüber den SSRI bei schweren und therapieresistenten Depressionen. Bei Therapieresistenz ist eine Dosisoptimierung sowie eine Reevaluierung der Response nach längerfristiger Einnahme bei initialer SSRI-Behandlung wichtig. Durch eine Umstellung von TZA auf SSRI oder von einem auf einen anderen SSRI konnten Therapieerfolge beobachtet werden. SSRI gehen möglicherweise mit einer erhöhten Suizidgefährdung zumindest bei einem Teil der Patienten einher und sollten daher individuell unter enger Therapieüberwachung angewandt werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Adli M, Langlitz N, Bauer M, Baethge C (2005) High-dose antidepressant treatment in therapy-resistant patients with major depression — a review. Eur Arch Psychiatry Clin Neuroscience (in press)

    Google Scholar 

  • AHCPR (1993) Depression in primary care, vol 2: Treatment of major depression. Washington DC, US Department of Health and Human Services

    Google Scholar 

  • Altamura AC, Montgomery SA, Wernicke JF (1988) The evidence for 20 mg of fluoxetine as the optimal dose in the treatment of depression. Brit J Psychiatry 153[Suppl 3]: 109–112

    Google Scholar 

  • Anderson IM (1998) SSRIs versus tricyclic antidepressants in depressed in-patients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7[Suppl 1]: 11–17

    Article  PubMed  Google Scholar 

  • Anderson IM (2000) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Aff Disord 58: 19–36

    Article  Google Scholar 

  • Azorin JM, Llorca PM, Despiegel N, Verpillat P (2004) Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder. Encephale 30: 158–166

    PubMed  Google Scholar 

  • Baker CB, Woods SW (2003) Is there a SSRI dose response in treating major depression? The case for re-analysis of current data and for enhancing future study design. Depress Anxiety 17: 10–18

    Article  PubMed  Google Scholar 

  • Baker CB, Tweedie R, Duval S, Woods SW (2003) Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis. Depress Anxiety 17: 1–9

    Article  PubMed  Google Scholar 

  • Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP, Geddes JR, Hardy R, Lewis G, Mason JM (2004) Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TZA) (Cochrane Review). In: The Cochrane Library, Issue 2. John Wiley & Sons, Ltd., Chichester, UK

    Google Scholar 

  • Bauer M, Hellweg R, Baumgartner A (1996) Fluoxetine-induced akathisia does not reappear after switch to paroxetine. J Clin Psychiatry 57: 593–594

    Google Scholar 

  • Beasley CM, Sayler ME, Cunningham GE, Weiss AM, Masica DN (1990) Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord 20: 193–200

    Article  PubMed  Google Scholar 

  • Beasley CM, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH Jr, Heiligenstein JH, Thompson VL, Murphy DJ, Masica DN (1991) Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. Brit Med J 303: 685–692

    PubMed  Google Scholar 

  • Boyer WF, Feighner JP (1991) The efficacy of selective serotonin re-uptake inhibitors in depression. In: Feighner JP, Boyer WF (eds) Selective serononin re-uptake inhibitors. Wiley & Sons, Chichester, pp 89–108

    Google Scholar 

  • Brown WA, Harrison W (1995) Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 56: 30–34

    Google Scholar 

  • Brown GK, Beck AT, Steer RA, Grisham JR (2000) Risk factors for suicide in psychiatric outpatients: a 20-year prospective study. J Consult Clin Psychol 68: 371–377

    Article  PubMed  Google Scholar 

  • Coulter DM, Pillans PI (1995) Fluoxetine and extrapyramidal side effects. Am J Psychiatry 152: 122–125

    PubMed  Google Scholar 

  • Crimson ML, Trivedi M, Pigott TA, Rush AJ, Hirschfeld RM, Kahn DA, DeBattista C, Nelson JC, Nierenberg AA, Sackeim HA, Thase ME (1999) The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 60: 142–156

    PubMed  Google Scholar 

  • Delgado PL, Price LH, Charney DS, Heninger GR (1988) Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 15: 55–60

    Article  PubMed  Google Scholar 

  • Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF (1989) Effect of dose-escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 25: 71–79

    PubMed  Google Scholar 

  • Fava M, Rosenbaum JF, McGrath PJ, Stewart JM, Amsterdam JD, Quitkin FM (1994) Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 151: 1372–1374

    PubMed  Google Scholar 

  • Fuller RW, Wong DT (1987) Serotonin reuptake blockers in vitro and vivo. J Clin Psychopharmacol 7: 14–20

    Google Scholar 

  • Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (2004) Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression (Cochrane Review). In: The Cochrane Library, Issue 2., John Wiley & Sons, Ltd., Chichester, UK

    Google Scholar 

  • Gotzsche PC (1989) Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinfl ammatory drugs in rheumatoid arthritis. Control Clin Trials 10: 31–56

    Article  PubMed  Google Scholar 

  • Healy D, Whitacker C (2003) Antidepressants and suicide: riskbenefit conundrums. J Psychiatry Neurosci 23: 331–337

    Google Scholar 

  • Hirschfeld RM (1999) Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TZA. J Clin Psychiatry 60: 326–335

    PubMed  Google Scholar 

  • Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, Hawley C, Kasper S, Linden M, Massana J, Mendlewicz J, Möller HJ, Nemeroff CB, Saiz J, Such P, Torta R, Versiani M (2002) Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 63: 826–837

    PubMed  Google Scholar 

  • Joffe RT, Levitt AJ, Sokolov ST, Young LT (1996) Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 57: 114–115

    PubMed  Google Scholar 

  • Joyce PR, Mulder RT, Luty SE, McKenzie JM, Rae AM (2003) A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender. Acta Psychiatr Scand 108: 20–23

    Article  PubMed  Google Scholar 

  • Kessler RC, Borges G, Walters EE (1999) Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry 56: 617–626

    Article  PubMed  Google Scholar 

  • Kienke AS, Rosenbaum JF (2000) Efficacy of venlafaxine in the treatment of severe depression. Depress Anxiety 12[Suppl 1]: 50–54

    Article  PubMed  Google Scholar 

  • Lane R, Baldwin D, Preskorn S (1995) The SSRIs: advantages, disadvantages and differences. J Psychopharmacol 9[Suppl]: 163–178

    Google Scholar 

  • Leitner I, Bailer U, Letmaier M, Stastny J, Aschauer H, Kasper S (2004) Behandlungsmöglichkeiten der therapieresistenten Depression. J Neurol Neurochir Psychiatry 5: 28–39

    Google Scholar 

  • Licht RW, Qvitzau S (2002) Treatment strategies in patients with major depression not responding to first-line sertraline treatment: a randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology 161: 143–151

    Article  PubMed  Google Scholar 

  • Lopez-Ibor JJ (1993) Reduced suicidality on paroxetine. Eur Psychiatry 1[Suppl 8]: 17–19

    Google Scholar 

  • Mann JJ, Waternaux C, Haas GL, Malone KM (1999) Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 156: 181–189

    PubMed  Google Scholar 

  • McCombs JS, Nicol MB, Stimmel GL, Sclar DA, Beasley CM, Gross LS (1990) The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in the Medicaid population. J Clin Psychiatry 51[Suppl 6]: 60–69

    PubMed  Google Scholar 

  • Montgomery SA, Dunner DL, Dunbar G (1995) Reduction of suicidal thoughts with paroxetine in comparison to reference antidepressants and placebo. Eur Neuropsychopharmacol 5: 5–13

    Article  PubMed  Google Scholar 

  • Nelson JC (1997) Treatment of refractory depression. Depress Anxiety 5: 165–174

    Article  PubMed  Google Scholar 

  • Nelson JC (1998) Overcoming treatment resistance in depression. J Clin Psychiatry 59[Suppl 16]: 13–19; discussion 40–42

    Google Scholar 

  • Nelson JC (2003) Managing treatment-resistant major depression. J Cin Psychiatry 64[Suppl 1]: 5–12

    Google Scholar 

  • Nolen WA, van de Pute JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, Haffmans J (1988) Treatment strategy in depression. Acta Psychiatr Scand 78: 668–675

    PubMed  Google Scholar 

  • Parker G (2002) Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiatr Scand 106: 168–170

    Article  PubMed  Google Scholar 

  • Peselow ED, Filippi AM, Goodnick P, Barouche F, Fieve RR (1989) The short-and long-term efficacy of paroxetine HC: data from a double-blind crossover study and from a year-long term trial vs imipramine and placebo. Psychopharmacol Bull 25: 272–276

    PubMed  Google Scholar 

  • Reimherr FW, Wood DR, Byerley B, Brainard J, Grosser BI (1984) Characteristics of responders to fluoxetine. Psychopharmacol Bull 20: 70–72

    PubMed  Google Scholar 

  • Rickels K, Schweizer E (1990) Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 51[Suppl B]: 9–12

    Google Scholar 

  • Roose SP, Glassman AH, Attia E, Woodring S (1994) Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 151: 1735–1739

    PubMed  Google Scholar 

  • Salize HJ, Stamm K, Schubert M, Bergmann F, Härter M, Berger M, Gaebel W, Schneider F (2004) Behandlungskosten von Patienten mit Depressionsdiagnose in haus-und fachärztlicher Versorgung in Deutschland. Psychiat Prax 31: 147–156

    Google Scholar 

  • Schwabe U, Paffrath D (Hrsg) (2003) Arzneiverordnungsreport 2002. Springer-Verlag Berlin Heidelberg

    Google Scholar 

  • Stimpson N, Agrawal N, Lewis G (2002) Randomized controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression. Brit J Psychiatry 181: 284–294

    Article  Google Scholar 

  • Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG (1997) Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 58: 16–21

    Google Scholar 

  • Tyrer P, Marsden CA, Casey P, Seivewright N (1987) Clinical efficacy of paroxetine in resistant depression. J Psychopharmacol 1: 251–257

    Google Scholar 

  • Zarate CA, Kando JC, Tohen M, Weiss MK, Cole JO (1996) Does intolerance or lack of response with fluoxetine predict the same will happen to sertraline? J Clin Psychiatry 57: 67–71

    PubMed  Google Scholar 

Download references

Authors
  1. A. Pfennig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Baethge
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Psychatrie und Psychotherapie, Charité — Universitätsklinik Berlin, Campus Charité Mitte (CCM), Schumannstr. 20/21, 10117, Berlin

    Michael Bauer  & Mazda Adli  & 

  2. Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie, Charité — Universitätsklinik Berlin, Campus Charité Mitte (CCM), Luisenstr. 57, 10117, Berlin

    Anne Berghöfer

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Pfennig, A., Bauer, M., Baethge, C. (2005). Selektive Serotonin-Wiederaufnahmehemmer bei therapieresistenten und schweren Depressionen. In: Bauer, M., Berghöfer, A., Adli, M. (eds) Akute und therapieresistente Depressionen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-28049-9_15

Download citation

  • DOI: https://doi.org/10.1007/3-540-28049-9_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40617-4

  • Online ISBN: 978-3-540-28049-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation